GlobeNewswire Inc.··Rosen Law FirmImmutep Stock Collapses 82.6% After Failed Cancer Trial, Triggering Class Action
Immutep's $IMMP shares plummeted after discontinuing Phase III trial for cancer drug. Rosen Law Firm investigates potential securities fraud claims.
IMMPinvestor lossessecurities class action